Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Janet Huffman
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3
- Beta
- 1.25
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -63.60
Financials
Revenue
$0.00Net Income
$-2.53MEBITDA
$-2.58MFree Cash Flow
$-2.19MEPS (diluted)
$-0.57Shares Outstanding (diluted)
4.43M+5310.1%Operating Expenses
$2.59MCash & Debt
$3.86MReturn of Capital
$0.00Revenue by Segment (annual)
$250.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-9.84M | $-4.56 |
| 2024 | $0.00 | $-10.57M | $-1.60 |
| 2023 | $0.00 | $-20.66M | $-9.18 |
| 2022 | $0.00 | $-14.29M | $-7.11 |
| 2021 | $0.00 | $-15.71M | $-8.09 |
| 2020 | $0.00 | $-26.43M | $-28.05 |
| 2019 | $0.00 | $-15.57M | $-22.10 |
| 2018 | $0.00 | $-9.91M | $-45.62 |
| 2017 | $0.00 | $-6.73M | $-81.99 |
| 2016 | $0.00 | $-7.01M | $-94.35 |
| 2015 | $1.18M | $-11.71M | $-192.00 |
| 2014 | $939.9K | $-5.79M | $-96.08 |
| 2013 | $1.03M | $-16.07M | $-335.02 |
| 2012 | $1.33M | $-13.09M | $-442.86 |
Valuation
OGENhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
90-25.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·20d ago·Negative
Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum Presentation Highlights Clinical Translation of ONP-002 Intranasal Delivery Platform for Concussion Treatment James P. Kelly, MD, Chief Medical Officer of Oragenics, is scheduled to present in the Successful Case Studies session at the IPAC-RS 2026 Nasal Innovation Forum on Thursday, September 17, 2026 Presentation is expected to address development and clinical translation of ONP-002, including the intranasal deli
View source ↗ - Newsglobenewswire.com·38d ago·Positive
Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update SARASOTA, Fla., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company developing brain-targeted therapeutics through its proprietary intranasal delivery platform, today provided an update on its Phase IIa clinical trial, U.S. regulatory pathway, and NYSE American continued listing status.
View source ↗ - Newsdefenseworld.net·55d ago·Positive
Oragenics (NYSEAMERICAN:OGEN) Trading Up 0.2% – Time to Buy? Shares of Oragenics, Inc. (NYSEAMERICAN:OGEN - Get Free Report) traded up 0.2% on Tuesday. The stock traded as high as $0.5490 and last traded at $0.5489. 31,024 shares changed hands during mid-day trading, an increase of 28% from the average daily volume of 24,280 shares. The stock had previously closed at $0.5480. Oragenics Trading
View source ↗
Earnings
Mon, Nov 16(in 6 weeks)
Consensus estimate $-90.00 per share
Typical surprise +99.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.57 vs $-90.00beat
- Fri, May 8$-0.51 vs $-90.00beat
- Thu, Feb 26$-0.54 vs $-90.00beat
- Fri, Nov 7$-1.96 vs $-144.00beat
Estimates and results for OGEN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by OGEN officers and directors.
- Bought
- $607k
- Sold
- $307k
11 trades
19 trades
- Telling Fredsold
- Telling Fredsold
- Odyssey Health, Inc.sold
- Odyssey Health, Inc.sold
- Odyssey Health, Inc.sold
- Odyssey Health, Inc.sold
- Dunton Alan Wsold
- Telling Fredsold
70 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in OGEN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.